Reply to D. Przepiorka et al and M.K. Jensen

Comment

Alan K Burnett et al. J Clin Oncol. 2013.

. 2013 May 1;31(13):1700-1; discussion 1701.

doi: 10.1200/JCO.2013.48.6571.

No abstract available

Comment on

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L, Hunter AE, Yin J, Craddock CF, Dufva IH, Wheatley K, Milligan D. Burnett AK, et al. J Clin Oncol. 2012 Nov 10;30(32):3924-31. doi: 10.1200/JCO.2012.42.2964. Epub 2012 Jul 30. J Clin Oncol. 2012. PMID: 22851554 Clinical Trial.
Gemtuzumab ozogamicin.
Przepiorka D, Deisseroth A, Kane R, Kaminskas E, Farrell AT, Pazdur R. Przepiorka D, et al. J Clin Oncol. 2013 May 1;31(13):1699-700. doi: 10.1200/JCO.2012.48.1887. Epub 2013 Mar 25. J Clin Oncol. 2013. PMID: 23530094 No abstract available.
No evidence of survival benefit with addition of gemtuzumab ozogamicin to standard medical research council induction chemotherapy.
Jensen MK. Jensen MK. J Clin Oncol. 2013 May 1;31(13):1700. doi: 10.1200/JCO.2012.47.9238. Epub 2013 Mar 25. J Clin Oncol. 2013. PMID: 23530103 No abstract available.